December 22, 2016 / 10:18 PM / 7 months ago

BRIEF-Cel-Sci says FDA issued incomplete response to hold letter to co

1 Min Read

Dec 22 (Reuters) - Cel-sci Corp :

* On December 16, FDA issued incomplete response to hold letter to co

* Cel-Sci Corp - FDA's incomplete response to hold letter indicates co's Nov 18 submission is not complete response to all issues listed in FDA's clinical hold letter

* Cel-Sci Corp- plans to send FDA a request for an in person meeting with agency to discuss all matters relating to partial clinical hold

* Cel-Sci Corp- should FDA lift partial clinical hold remaining cost of phase 3 clinical trial will be higher than currently estimated

* Cel-Sci Corp- reviewing all options in response to FDA's incomplete response to hold letter - sec filing

* Cel-Sci Corp- estimate total remaining cash cost of phase 3 clinical trial, excluding any costs to be paid by partners, would be about $12.1 million Source text - bit.ly/2hhyUFY Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below